13.89

0.29% +0.04

After Hours: 13.89

abrdn Life Sciences Investors (HQL)

Overview News Price History Discussions Forecast Dividend History

abrdn Life Sciences Investors stock is currently priced at $13.89, with a 24-hour trading volume of 102.60K. It has seen a +0.29% increased in the last 24 hours and a +6.76% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $13.86 pivot point. If it approaches the $13.91 resistance level, significant changes may occur.

Previous Close:

$13.85

Open:

$13.83

24h Volume:

102.60K

Market Cap:

$379.90M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+1.61%

1M Performance:

+6.76%

6M Performance:

+16.92%

1Y Performance:

+0.22%

1D Range:

$13.83

$13.95

52W Range:

$11.34

$14.37

abrdn Life Sciences Investors Stock (HQL) Company Profile

Name

abrdn Life Sciences Investors

Sector

Financial (4542)

Industry

Closed-End Fund - Equity (123)

Phone

617-772-8500

Address

100 Federal Street, 19th Floor, Boston, MA

Employee

Twitter

Next Earnings Date

2024-06-03

Latest SEC Filings

HQL's Discussions on Twitter

abrdn Life Sciences Investors Stock (HQL) Financials Data

There is no financial data for abrdn Life Sciences Investors (HQL). Check out other stocks for more information.

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.